Table 1.
Baseline PCNSL patient characteristics
| Characteristics | Total* | Early mortality (60 days) | Non-early mortality |
|---|---|---|---|
| n = 133 | n = 13 | n = 120 | |
| n (%) | n (%) | n (%) | |
| Median age, years (range) | 64 (22-88) | 70 (44-87) | 64 (22-88) |
| ≥ 80 | 16 (12.0) | 4 (30.8) | 12 (10.0) |
| < 80 | 117 (88.0) | 9 (69.2) | 108 (90.0) |
| Sex | |||
| Male | 75 (56.4) | 8 (61.5) | 67 (55.8) |
| Female | 58 (43.6) | 5 (38.5) | 53 (44.2) |
| Site | |||
| Frontal lobe | 51 (38.4) | 5 (38.5) | 46 (38.3) |
| Parietal lobe | 37 (27.8) | 3 (23.1) | 34 (28.3) |
| Temporal lobe | 37 (27.8) | 4 (30.8) | 45 (37.5) |
| Occipital lobe | 23 (17.3) | 4 (30.8) | 21 (17.5) |
| Basal ganglia | 49 (36.8) | 9 (69.2) | 40 (33.3) |
| Brain stem | 17 (12.8) | 2 (15.4) | 15 (12.5) |
| Cerebellum | 18 (13.5) | 3 (23.1) | 15 (12.5) |
| Meninges | 1 (0.8) | 0 (0.0) | 15 (12.5) |
| Cranial nerves | 2 (1.5) | 0 (0.0) | 2 (1.7) |
| Median max diameter (IQR) | 3.4 (2.6-4.5) | 4.0 (3.2-4.3) | 3.3 (2.6-4.5) |
| Number of lesions | |||
| 1 | 66 (49.6) | 8 (61.5) | 58 (48.3) |
| 2 | 27 (20.3) | 2 (15.4) | 25 (20.8) |
| 3 | 17 (12.8) | 0 (0.0) | 17 (14.2) |
| 4 | 8 (6.0) | 0 (0.0) | 8 (6.7) |
| ≥ 5 | 15 (11.3) | 3 (23.1) | 12 (10.0) |
| Deep brain lesions | 91 (68.4) | 11 (84.6) | 80 (66.7) |
| Midline shift | 46/131 (35.1) | 6/13 (46.2) | 40/118 (33.9) |
| Initial surgical management | |||
| Stereotactic biopsy | 85 (63.9) | 9 (69.2) | 76 (63.3) |
| Open biopsy | 6 (4.5) | 0 (0.0) | 6 (5.0) |
| Partial resection | 42 (31.6) | 4 (30.8) | 38 (31.7) |
| CSF involvement | 5/74 (6.8) | 0/2 (0.0) | 5/72 (6.9) |
| Intraocular involvement | 15/63 (23.8) | 0/4 (0.0) | 15/59 (25.4) |
| ECOG | |||
| 0-1 | 65 (48.9) | 2 (15.4) | 63 (52.5) |
| ≥ 2 | 68 (51.1) | 11 (84.6) | 57 (47.5) |
| Lab data, median (IQR) | |||
| White blood cell, /ul | 9,700 (7,200-13,200) | 10,400 (6,700-13,600) | 9,650 (7,200-13,150) |
| Hemoglobin, g/dl | 12.7 (11.4-14.1) | 12.0 (10.6-12.7) | 12.9 (11.7-14.1) |
| Platelet, /ul | 199,000 (157,000-270,000) | 171,000 (143,000-288,000) | 200,500 (158,000-268,500) |
| Albumin, g/dl | 3.7 (3.2-4.1) | 3.5 (3.0-3.8) | 3.8 (3.3-4.1) |
| Lactate dehydrogenase, U/L | 241.0 (198.0-317.0) | 265.0 (235.0-501.0) | 236.5 (194.5-312.5) |
| CSF protein, mg/dl | 66.9 (43.1-100.0) | 78.6 (74.3-241.1) | 63.5 (43.0-100.0) |
| First-line treatments | |||
| MTX | 104 (78.2) | 4 (30.8) | 100 (83.3) |
| Rituximab | 76 (57.1) | 2 (15.4) | 74 (61.7) |
| Vincristine | 22 (16.5) | 0 (0.0) | 22 (18.3) |
| Cyclophosphamide | 1 (0.8) | 0 (0.0) | 1 (0.8) |
| Cytarabine | 30 (22.6) | 0 (0.0) | 30 (25.0) |
| Corticosteroid | 127 (95.5) | 10 (76.9) | 117 (97.5) |
| Radiotherapy | 67 (50.4) | 2 (15.4) | 65 (54.2) |
IQR, interquartile range; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group performance; MTX, methotrexate. * Including some missing value